Volume 17, Number 4—April 2011
Dispatch
High Rates of Staphylococcus aureus USA400 Infection, Northern Canada
Table 2
MRSA PFGE epidemic types (MLST) | No. (%) related MSSA isolates | PVL positive | Predominant spa type† |
---|---|---|---|
CMRSA1/USA600 (ST45) | 38 (13.3) | 0 | t065 (n = 23) |
CMRSA2/USA100/800 (ST5) | 77 (26.9) | 0 | t311 (n = 46) |
CMRSA4/USA200 (ST36) | 30 (10.5) | 0 | t012 (n = 12) |
CMRSA7/USA400 (ST1) | 12 (4.2) | 12 | t128 (n = 8) |
CMRSA10/USA300 (ST8) | 3 (1.1) | 2 | t008 (n = 2) |
USA700 (ST72) | 1(0.4) | 0 | t148 (n = 1) |
ST97 | 18 (6.3) | 0 | t2728 (n = 11) |
USA1000 (ST59) | 33 (11.5) | 1 | t163 (n = 27) |
USA1100 (ST30) | 1 (0.4) | 0 | t122 (n = 1) |
*n = 286 MSSA isolates. MSSA, methicilin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus; PVL, Panton-Valentine leukocidin; PFGE, pulsed-field gel electrophoresis; MLST, multilocus sequence typing; ST, sequence type.
†www.ridom.de.
1Members of the Northern Antibiotic Resistance Partnership are listed at the end of this article.
Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.